IMB - Information for patients on safety monitoring of medicines
The Irish Medicines Board has posted information on its website explaining the updated legislation for monitoring the safety of medicines (Pharmacovigilance) which came into effect in Ireland and across the EU in July 2012 and the impact of this legislation for patients and consumers.
A key aspect of the new legislation is the important role of patients and consumers in contributing to the strengthened system of pharmacovigilance. This document explains the changes to the reporting of side effects (also known as adverse reactions) and the steps a patient or consumer can take to report them.
To view the full article on the website please click the following link: http://www.imb.ie/7453.htm. If this link does not work, please copy the URL into your browser.
Bookmark and Share 
|
